Accessibility Menu
Silence Therapeutics Plc logo

Silence Therapeutics Plc(NASDAQ) SLN

Market Cap$834.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-31%
5 Year-40%
1 Year+181%
1 Month+29%
Premium Feature
Moneyball Superscore
46/100
$13.52
+0.75%
+0.10Today
After hours$13.55+$0.03 (+0.22%)
Silence Therapeutics Plc last closing stock price
MetricPriceDate
Last closeUSD 13.532026-08-31
Silence Therapeutics Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.81%USD 13.292026-08-24
1 month+28.98%USD 10.492026-07-31
3 month+112.4%USD 6.372026-06-02
Year to date+122.53%USD 6.082025-12-31
1 year+181.29%USD 4.812025-08-29
3 year+59.18%USD 8.502023-09-01
5 year-40.13%USD 22.602021-09-01
Since inception-31.18%USD 19.502020-09-08

Silence Therapeutics Plc Financials at a Glance

Market Cap

$834.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$614.29K

Net Income (TTM)

-$59.95M

EPS (TTM)

-$1.27

P/E Ratio

-10.60

Dividend

$0.00

Beta (Volatility)

0.72 (Low)

Price

$13.52

Volume

478,194.786

Open

$13.39

Previous Close

$13.53

Daily Range

$13.09 - $13.65

52-Week Range

$4.19 - $17.58

Estimated Earnings Date

Nov 5, 2026

SLN News

Foolcom-Featured.png

Silence (SLN) Q2 Revenue Drops 71%

Motley Fool Markets TeamAug 7, 2025

SLN: Motley Fool Moneyball Superscore

46

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Silence Therapeutics Plc

Silence Therapeutics plc creates medicines to stop harmful protein production. These drugs help patients with blood disorders and heart disease. The company targets specific genes inside the liver.

Turning Down Disease-Causing Genes

  • Divesiran (SLN124): Experimental treatment for polycythemia vera, a rare blood-thickening condition.
  • Zerlasiran (SLN360): Drug candidate designed to lower a genetic risk factor for heart attacks.
  • SLN312: Asset for lipid metabolism disorders being returned to the company from a former partner.
  • SLN098: Early-stage program focused on fat loss while preserving muscle mass during obesity treatment.

Clinical Progress and Strategic Moves

  • Completed patient dosing for the Phase 2 trial of its blood disorder treatment in June 2026.
  • Announced in March 2026 that it will regain full global rights to its dyslipidemia treatment from AstraZeneca.
  • Entered into an agreement in March 2026 to potentially sell ordinary shares through Jefferies LLC.
  • Secured $120.0 million through a private placement of American Depositary Shares in February 2024.

Precision Medicine for the Liver

The company uses its proprietary delivery platform to target specific genes in the liver. This system focuses on natural biological processes to prevent the production of proteins that cause illness.

By the Numbers

  • Revenue was $0.4 million for the six-month period ended June 30, 2026.
  • Loss after taxation was $27.2 million for the six months ended June 30, 2026.
  • Research and development costs reached $18.3 million for the six months ended June 30, 2026.
  • Cash and cash equivalents totaled $72.1 million as of June 30, 2026.
  • Market capitalization was $518.7 million in Q2 2026, up 468.0% year over year.

Evolving From Research to Results

Silence Therapeutics has evolved from a research firm into a clinical-stage biotech company with several drugs in human trials. Its focus on liver-targeted gene silencing allows it to address multiple conditions through internal development and global partnerships.

AI Generated • Aug 10, 2026

Industry

Biotechnology

Sector

Health Care

Employees

88

CEO

Iain Gladstone Ross

Website

www.silence-therapeutics.com

Headquarters

London, GL W6 7AP, GB

SLN Financials

Key Financial Metrics (TTM)

Gross Margin

51.00%

Operating Margin

-10880.25%

Net Income Margin

-9759.23%

Return on Equity

-106.94%

Return on Capital

-143.69%

Return on Assets

-56.34%

Earnings Yield

-9.43%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$834.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

62.15M

Volume

478.19K

Avg. Volume

947.45K

Financials (TTM)

Gross Profit

$313.29K

Operating Income

-$66.84M

EBITDA

-$60.29M

Operating Cash Flow

-$42.29M

Capital Expenditure

-$58.00K

Free Cash Flow

-$42.34M

Cash & ST Invst.

$72.05M

Total Debt

$112.00K

Silence Therapeutics Plc Performance Analysis

Silence Therapeutics Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 21,557,38526.3%
20232023-12-31USD 31,765,65147.4%
20242024-12-31USD 43,276,20236.2%
20252025-12-31USD 560,306-98.7%
Silence Therapeutics Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-48.2%
Q42025-12-31-78.6%
Q12026-03-311139.1%
Q22026-06-30-100.0%
Silence Therapeutics Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.55-15.3%
20232023-12-31USD -1.47-5.3%
20242024-12-31USD -0.98-33.2%
20252025-12-31USD -1.8891.9%
Silence Therapeutics Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3045.0%
Q42025-12-3143.2%
Q12026-03-31-28.0%
Q22026-06-3018.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$108.20K

-156.8%

Gross Margin

0.00%

N/A

Market Cap

$834.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$9.48M

N/A

Employees

88

N/A

Net Income

-$12.29M

+67.2%

EBITDA

-$13.00M

+57.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$72.05M

-36.9%

Total Debt

$112.00K

N/A

Accounts Receivable

$9.29M

-53.6%

Inventory

$0.00

N/A

Long Term Debt

$9.00K

N/A

Short Term Debt

$103.00K

N/A

Return on Assets

-56.34%

N/A

Return on Invested Capital

-71.33%

N/A

Free Cash Flow

$1.49M

+106.8%

Operating Cash Flow

$1.49M

+106.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CTNMContineum Therapeutics, Inc.
$16.24-4.75%
CAPRCapricor Therapeutics, Inc.
$9.91+3.34%
KYTXKyverna Therapeutics, Inc.
$8.48+1.25%
ANROAlto Neuroscience, Inc.
$35.38+0.71%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About SLN

What is the current price of Silence Therapeutics Plc?

Silence Therapeutics Plc is trading at $13.53 per share.

What is the 52-week range for Silence Therapeutics Plc?

Over the past 52 weeks, Silence Therapeutics Plc has traded between $4.19 and $17.58.

How much debt does Silence Therapeutics Plc have?

As of the most recent reporting period, Silence Therapeutics Plc reported total debt of $112.00K.

How much cash does Silence Therapeutics Plc have on hand?

Silence Therapeutics Plc reported $72.05M in cash and cash equivalents in its most recent financial results.

What is Silence Therapeutics Plc’s dividend yield?

Silence Therapeutics Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services